Continuing Education Activity

Cannabis contains multiple biologically active compounds, most notably delta-9-tetrahydrocannabinol and cannabidiol, with divergent psychoactive and therapeutic effects. Despite remaining a Schedule I substance at the federal level, cannabis use has expanded rapidly due to widespread state legalization, increasing product potency, and shifting public perceptions. These trends have contributed to rising rates of cannabis use disorder, which affects a substantial proportion of regular users and is associated with neuropsychiatric, cardiovascular, cognitive, and functional harms, particularly among adolescents and individuals with psychiatric comorbidity. This course reviews cannabis pharmacology, epidemiology, regulation, and clinical implications of cannabis use disorder in modern practice. 

Additionally, this course outlines the neurobiological, genetic, and psychosocial factors underlying cannabis use disorder, high-risk populations, common clinical presentations of cannabis use disorder, and validated screening and diagnostic tools in diverse care settings. Participants will also gain an understanding of evidence-based management strategies, including first-line psychosocial treatments, harm reduction principles, and the distinction between medical cannabinoid use and disordered use, supporting safer, more informed, and patient-centered clinical decision-making. This activity for healthcare professionals is designed to enhance the learner's competence in identifying cannabis use disorder, performing the recommended evaluation and screening, and implementing an appropriate interprofessional approach when managing this condition to improve patient outcomes.

Objectives:

• Identify the neurobiological mechanisms contributing to cannabis use disorder.
• Screen patients using validated tools to detect cannabis use disorder across clinical settings.
• Apply evidence-based treatment modalities to promote recovery in patients with cannabis use disorder.
• Coordinate interprofessional management strategies to improve care collaboration and outcomes in patients with cannabis use disorder.

Introduction

Cannabis contains numerous biologically active constituents, most notably delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC mediates most psychoactive effects via CB1 receptor agonism. CBD is nonintoxicating and may modulate THC effects through several mechanisms (eg, low-affinity cannabinoid receptor interactions and serotonergic signaling), though clinical effects depend on dose and formulation.[1]

Cannabis remains Schedule I federally; state laws vary; FDA-approved cannabinoids exist for limited indications.[FDA. FDA and Cannabis: Research and Drug Approval Process. 2023] Despite these exceptions, cannabis use continues to expand rapidly amid shifting public perception and widespread state legalization.

As of February 2024, the Centers for Disease Control and Prevention (CDC) reports that 47 states, the District of Columbia, and 3 territories permit some form of medical cannabis use. Among these, 38 states, the District of Columbia, and 3 territories operate comprehensive medical programs allowing cannabis products beyond low-THC or CBD-only formulations. Additionally, 24 states, 2 territories, and the District of Columbia have legalized nonmedical (adult-use) cannabis through state or territorial legislation.[CDC. State Medical Cannabis Laws. 2024]

Globally, cannabis is the fourth most commonly used psychoactive substance after alcohol, caffeine, and tobacco, with an estimated 147 million users worldwide, although global prevalence estimates have continued to rise.[WHO. Alcohol, Drugs and Addictive Behaviours. 2016] Over the past 2 decades, the average THC potency of cannabis products has increased 3- to 5-fold, amplifying the risk of neuropsychiatric, cardiovascular, and cognitive complications.[2]

Cannabis Use Disorder

Among regular users, estimates suggest that approximately 20% to 30% may meet criteria for CUD, with risk increasing with daily use, early initiation, and high-potency products.[3] Psychosocial interventions, including cognitive behavioral therapy (CBT), motivational enhancement therapy, and contingency management, remain first-line treatments. However, as of 2025, no pharmacologic therapy is FDA-approved for CUD. Trials of THC analogs, cannabidiol, gabapentin, N-acetylcysteine, and antidepressants have shown inconsistent or modest benefit.[4] The rising prevalence of CUD, occurring alongside expanded legalization and diminishing perceived risk, underscores the need for early screening, patient education, and coordinated interprofessional management.

Historically, cannabis has been cultivated for medical, spiritual, and industrial purposes. The modern resurgence of scientific and clinical interest reflects these traditional uses but demands rigorous evidence-based evaluation to distinguish legitimate therapeutic benefit from misuse.[WHO. WHO Review of Cannabis and Cannabis-Related Substances. 2019][3]

Etiology

CUD develops through the interaction of biological, genetic, and psychosocial factors that influence the initiation and persistence of use. Vulnerability is most significant during adolescence and among individuals with psychiatric comorbidities or environmental exposure to substance use.

Biological Factors

THC, the primary psychoactive cannabinoid, stimulates cannabinoid type-1 (CB1) receptors within corticolimbic circuits that regulate reward and executive control. Repeated exposure disrupts endocannabinoid signaling and inhibitory regulation, fostering tolerance and withdrawal. High-potency products (>15%–20% THC) and concentrated formulations such as oils and distillates increase CUD risk in a dose-response pattern and are associated with greater psychiatric morbidity.[5]

Genetic Factors

CUD shows substantial heritability (approximately 30%–80%). Estimates vary by study design and phenotype. Genome-wide studies identify polygenic risk involving dopaminergic, glutamatergic, and endocannabinoid pathways (eg, CNR1, FAAH, DRD2) that overlap with vulnerability to other substance use and psychiatric disorders.[6][7][8] Environmental factors, eg, stress, peer influence, and substance availability, further modulate expression of this genetic risk.

Psychosocial and Environmental Factors

Early exposure to parental or peer substance use, adverse childhood experiences, and socioeconomic disadvantage increases risk. National data confirm that social engagement, curiosity, and stress relief remain predominant motives among adolescents and young adults.[SAMHSA. Marijuana and CBD. 2025] Perceived safety contributes to cannabis use among some pregnant individuals seeking relief of nausea or anxiety despite potential fetal neurodevelopmental harm.[9][10] Inhalation routes (smoked or vaped) deliver THC rapidly and at higher concentrations than oral ingestion, heightening dependence potential.[11]

Psychiatric Comorbidity and Special Populations

CUD frequently coexists with depression, anxiety, bipolar disorder, psychosis, and posttraumatic stress disorder, and these comorbidities are associated with more severe clinical courses and poorer functional outcomes.[12][13][14][15] Cannabis use is also prevalent among individuals receiving opioid agonist therapy and may reduce treatment adherence and recovery rates.[16] High-risk populations include adolescents, pregnant individuals, patients with chronic pain or opioid use disorder, people with HIV, and those with multiple sclerosis, among whom approximately 10% to 20% of users meet diagnostic criteria for CUD.

Epidemiology

Cannabis is among the most widely used psychoactive substances worldwide. In the United States, the 2023 National Survey on Drug Use and Health (NSDUH) reported that 15.4% of individuals aged 12 years or older (43.6 million) used marijuana in the past month and 61.8 million in the past year.

Approximately 6.8% (19.2 million) met criteria for past-year marijuana use disorder (cannabis use disorder), with the highest prevalence (16.6%) among adults aged 18 to 25 years. Daily and near-daily use (primary drivers of cannabis addiction) has increased since 2015, paralleling expanded legalization, commercialization, and rising product potency.[SAMHSA. Key Substance Use and Mental Health Indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. 2024]

Adolescents remain particularly vulnerable. The Monitoring the Future 2023 survey found that 14% to 15% of United States high-school students reported past-month use, and cannabis vaping has increased substantially since 2017. Initiation before age 15 is associated with approximately double the lifetime risk of CUD compared with later initiation.[NIH. Monitoring the Future. 2024] Among adults aged 50 and older, prevalence has more than doubled since 2015, often for perceived medical benefits, raising concerns about intoxication, falls, polypharmacy, and drug interactions.[17] 

Prenatal cannabis use rose from 1.3% in 2002 to about 7% in 2018. Because THC crosses the placenta and concentrates in breast milk, both the American College of Obstetricians and Gynecologists and the American Academy of Pediatrics (2023) recommend complete abstinence during pregnancy and lactation.[18][19] Unintentional pediatric ingestion has increased sharply, with thousands of reported exposures in children younger than 6 years between 2017 and 2022, underscoring the need for child-resistant packaging and safe storage.[20][21] Jurisdictions with legalization have shown higher rates of cannabis use and CUD in some studies, with disproportionate impact among young adults and individuals with comorbid mental illness.[22]

Pathophysiology

Neurobiology

Chronic cannabis exposure induces adaptive changes in reward, stress, and executive circuits that sustain tolerance and compulsive use. The psychoactive compound THC binds to CB1 and cannabinoid type-2 (CB2) receptors. CB1 receptors are dense in cortical, limbic, and striatal regions, whereas CB2 receptors are predominantly expressed in immune cells; CNS expression is lower but can be upregulated in inflammation.[23][1]

Receptor Signaling

CB1 activation inhibits adenylyl cyclase, lowers cyclic AMP levels, and modulates calcium and potassium channels, thereby suppressing presynaptic release of gamma-aminobutyric acid (GABA) and glutamate. These actions indirectly affect dopaminergic tone in the mesocorticolimbic pathway, influencing reward, motivation, and stress.[24]

Reinforcement and Withdrawal

THC indirectly increases mesolimbic dopamine signaling. Repeated exposure downregulates CB1 receptors, producing tolerance.[25] Withdrawal results from reduced endocannabinoid tone and CRF-driven amygdalar hyperactivity, leading to irritability, anxiety, and insomnia. 

Neuroimmune and Glial Effects

Microglia and astrocytes mediate endocannabinoid signaling. Persistent activation promotes cytokine release, neuroinflammation, and synaptic remodeling, impairing executive control.[26]

Adolescent Vulnerability

During adolescence, the endocannabinoid system guides pruning and myelination. Cannabis exposure disrupts these processes, causing lasting prefrontal–striatal changes and increasing lifetime risk for mood, cognitive, and substance-use disorders.[27][28]

Potency and Route

High-THC products (≥15%–20%) and concentrates cause rapid CB1 occupancy and greater corticolimbic disruption. Inhalation delivers faster, higher peaks than ingestion, heightening the potential for dependence.[29][11]

Cannabinoid Hyperemesis Syndrome

Cannabinoid hyperemesis syndrome results from chronic dysregulation of CB1-mediated gut–brain emetic pathways and altered TRPV1 signaling. The temporary relief achieved with hot bathing is attributed to TRPV1 activation, whereas complete and sustained resolution requires cessation of cannabis use.[30]

Functional and Genetic Changes

Neuroimaging shows reduced connectivity between the prefrontal cortex and the anterior cingulate cortex, as well as altered striatal activity, paralleling deficits in attention and motivation. Genetic and epigenetic studies link cannabis use to psychotic and affective disorders.[31] CUD results from convergent neurobiological and genetic mechanisms. Chronic THC exposure disrupts reward and stress regulation via CB1 downregulation, neuroimmune activation, and developmental interference. The endocannabinoid system remains a key target for future therapeutic strategies.[1]

Toxicokinetics

Cannabis contains numerous bioactive compounds, chiefly THC and CBD. Unlike standardized pharmaceutical derivatives, whole-plant cannabis has variable composition, complicating pharmacologic study. Most pharmacokinetic data derive from THC, the primary psychoactive component responsible for reinforcing effects, as Schedule I restrictions limit whole-plant research.[32]

Absorption and Distribution

The absorption and distribution of THC and CBD vary according to the following modalities of use:

• Inhalation: Rapid pulmonary absorption yields peak plasma THC within 5 to 10 minutes. Vaping or “dabbing” concentrated extracts (60%–80% THC) produces higher peaks and greater reinforcing potential.[33]
• Oral ingestion: Absorption is slower and variable, peaking at 2 to 6 hours. First-pass metabolism prolongs effects and increases the risk of overconsumption due to delayed onset.[34]
• Distribution: Highly lipophilic THC rapidly partitions into the brain, liver, and adipose tissue; about 97% is protein-bound. Bioavailability varies with inhalation depth, food intake, and metabolic rate.

Metabolism and Elimination

THC is oxidized mainly by CYP2C9, CYP2C19, and CYP3A4, forming active 11-hydroxy-THC and inactive 11-nor-9-carboxy-THC (THC-COOH).[35] Glucuronidation and biliary or renal excretion follow. Lipid sequestration and enterohepatic recirculation prolong exposure. Effective half-life varies; metabolites can persist for weeks.[36][33]

Chronic Exposure and Tolerance

Repeated use downregulates and desensitizes CB1 receptors, reducing responsiveness and promoting dose escalation. Slow release of stored THC contributes to delayed withdrawal and prolonged cognitive effects characteristic of CUD.[25]

Influencing Factors and Toxicity

Pharmacokinetics vary by route (inhalation produces rapid effects, whereas oral ingestion produces delayed and more prolonged effects), potency (eg, ≥15%–20% THC), formulation, genetic polymorphisms, and coingestants (eg, alcohol).[37] Adulterated vape oils containing vitamin E acetate or synthetic cannabinoids can cause e-cigarette or vaping product use-associated lung injury (EVALI), while high plasma THC levels correlate with tachyarrhythmia, hypotension, and ischemic events.[38]

THC’s lipophilicity, wide tissue distribution, extensive metabolism, and slow elimination sustain psychoactive effects for days or weeks. These kinetics, combined with CB1 desensitization and rising product potency, underlie the chronicity, withdrawal, and treatment challenges of CUD.[29][25]

History and Physical

Clinical assessment of CUD begins with identification of the phase of use, including acute intoxication, chronic or heavy use, or withdrawal, accompanied by a focused mental status evaluation.[39] During intoxication, patients may exhibit euphoria or anxiety, laughter, increased appetite, inattention, restlessness, tachycardia, conjunctival injection, and dry mouth, with occasional illusions or brief hallucinations that preserve reality testing. Chronic use or withdrawal commonly presents with depressed mood, apathy, irritability, poor concentration, and social withdrawal.[40][41][42]

Brief cognitive screening, eg, 3-word recall or short-story recall, may reveal deficits in attention or memory. Persistent affective symptoms during periods of abstinence suggest an underlying primary psychiatric disorder, and evaluation should always include assessment of suicide or violence risk. High-potency concentrates administered by vaping or dabbing produce faster onset and more severe effects than smoked or edible formulations.

Key History Elements

Clinical history components in patients with suspected CUD include characterization of use patterns and severity, encompassing frequency, potency, route of administration, escalation, failed cessation attempts, and functional consequences. Risk assessment should address coingestants, pediatric exposure, impaired driving, medical comorbidities, cardiovascular symptoms, and pregnancy or lactation status. Clinicians should perform a safety evaluation screening for suicidality, psychosis, agitation, panic, or delirium, along with consideration of legal or occupational implications related to impairment or testing. Moreover, cyclic vomiting relieved by hot bathing and recurring after use suggests cannabinoid hyperemesis syndrome, warranting exclusion of gastrointestinal or metabolic causes.

Focused Physical Examination

Targeted physical examination emphasizes vital signs, including tachycardia, transient hypertension, hydration status, and level of consciousness. Head and neck assessment may reveal conjunctival injection or xerostomia. The neurologic and mental status examinations should evaluate orientation, attention, memory, and impulsivity. Cardiopulmonary assessment addresses chest pain or respiratory distress, recognizing that chronic vaping or smoking may precipitate pneumothorax. In pediatric patients, vigilance for central nervous system depression or respiratory failure remains essential, with careful evaluation of exposure sources.

Typical Presentations

Typical intoxication presents with impaired coordination, euphoria or anxiety, altered time perception, and impaired judgment, accompanied by at least 2 physical signs, eg, conjunctival injection, dry mouth, tachycardia, or increased appetite. Withdrawal following heavy use typically manifests with 3 or more symptoms within 1 week, including irritability, anxiety, insomnia, appetite loss, restlessness, or depressed mood, plus at least 1 physical symptom, eg, abdominal pain, tremor, sweating, fever, chills, or headache. Symptom onset occurs within 24 hours, peaks by day 3, and resolves over approximately 2 weeks.[40]

Cannabis-Induced Psychiatric Syndromes

Cannabis exposure may precipitate transient substance-induced delirium, psychosis, anxiety, or sleep disturbance during intoxication or withdrawal when symptom severity exceeds expected effects. Ongoing psychotic symptoms beyond periods of use favor a primary psychiatric disorder.[43] Accurate diagnosis and management depend on determining the phase of use, assessing safety, documenting patterns, potency, and functional impact, recognizing cannabinoid hyperemesis syndrome and psychiatric manifestations, and distinguishing substance-induced symptoms from primary mental illness.

Evaluation

Evaluation of CUD integrates validated screening tools, structured diagnostic interviews, and clinical judgment to distinguish problematic use from therapeutic or recreational consumption. According to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), CUD is a chronic, relapsing condition marked by impaired control and continued use despite harm. Diagnosis requires at least 2 of 11 criteria within 12 months across 4 domains—impaired control, social or occupational dysfunction, risky use, and tolerance or withdrawal.[44][45]

The severity of CUD is classified as mild (2–3 criteria), moderate (4–5), or severe (≥6); sustained remission denotes the absence of CUD criteria for 12 months or more (see Table 1).[46][47][45]

Table

Table 1. DSM-5 Diagnostic Criteria, Severity Classification, and Remission Specifiers for Cannabis Use Disorder.

Screening and Initial Assessment

Screening should occur privately and nonjudgmentally, prompted by behavioral or physical indicators such as cognitive decline, conjunctival injection, cannabis odor, tachycardia, impaired coordination, or hyperphagia. Validated tools include:

• SIS-C: Single-item past-year use screen (sensitivity 0.88, specificity 0.83) [48]
• CUDIT-R: Contains 8 items on consumption and consequences (cutoff ≥9 for young adults; 10–14 for veterans) [49]
• CUDIT-C: A 3-item version for rapid assessment (sensitivity 0.91, specificity 0.84)
• ASSIST: Multisubstance tool validated for cannabis in primary care [50]

Positive screens warrant detailed interviews assessing frequency, dose, route, potency, motives, and functional effects. Screening identifies risk but does not confirm diagnosis.

Laboratory Testing and Interpretation

Toxicology confirms exposure but not intoxication or severity. The following specimens have varying detection windows:

• Urine: THC-COOH is detectable for approximately 3 days after a single use and up to 30 days in chronic users.
• Blood/saliva: Detection in these specimens reflects recent use (<24 hours); mainly forensic or occupational use.
• Hair: Detection in hair samples indicates long-term exposure without temporal precision.[51]

Results confirm exposure only; negative tests do not exclude use. Quantitative levels may approximate tolerance but are unreliable. Prototype breath tests for recent (<3 hours) use remain investigational. Routine laboratory studies are unnecessary unless psychosis, cognitive changes, or systemic illness warrant targeted evaluation (eg, metabolic, hepatic, or infectious panels).[52]

Structured Diagnostic Evaluation

Assessment should quantify patterns of use, craving, withdrawal symptoms, and the degree of functional impairment. Structured diagnostic interviews, such as the CIDI-SAM, align clinical findings with DSM-5-TR criteria and support consistent grading of disorder severity.[45] Notably, tolerance or withdrawal related to prescribed cannabinoid therapy does not indicate cannabis use disorder unless accompanied by impaired control, distress, or functional consequences.

Psychometric and Dimensional Validation

Psychometric and dimensional analyses support a single continuum of severity across DSM-5-TR criteria.[45] Highly discriminative features include craving, unsuccessful attempts to cut down, and continued use despite harm. Rasch and item-response modeling demonstrate reliability across diverse populations.[53] Tolerance and withdrawal contribute variable diagnostic weight, while cluster analyses identify subgroups characterized predominantly by craving and withdrawal or by social and occupational dysfunction, highlighting the need for individualized assessment approaches.[47]

Special Populations

Special populations require tailored evaluation strategies. In patients with psychotic or mood disorders, verification of temporal relationships between cannabis exposure and symptom onset using collateral information or toxicology improves diagnostic accuracy. Among veterans, the CUDIT-R remains a valid screening tool and should be integrated with assessment for posttraumatic stress disorder and depression.[54][55] In emergency and trauma settings, routine screening enhances detection among injured or impaired drivers.[56]

Evaluation Overview

A comprehensive evaluation of cannabis use disorder integrates validated screening instruments, eg, the SIS-C, CUDIT-R, or CUDIT-C, and ASSIST; structured diagnostic interviews, including the CIDI-SAM; context-specific toxicology testing; and thorough functional and contextual assessment. Knowledge of THC pharmacokinetics, interpretation of results within clinical context, and recognition of population-specific patterns, including adolescents, veterans, and individuals with psychiatric comorbidity, enhance diagnostic precision and support individualized management.

Treatment / Management

Goals and Care Settings

Management of CUD relies on evidence-based psychosocial interventions, notably cognitive behavioral therapy (CBT), motivational enhancement therapy, and their combination with contingency management as a key adjunct. Supportive care during intoxication and withdrawal, structured monitoring, and concurrent management of psychiatric comorbidities are essential. Pharmacologic and neuromodulation therapies remain investigational, with no FDA-approved options. Given persistently low treatment engagement and rising prevalence, clinicians should emphasize accessible, integrated, and culturally responsive care pathways.

The primary objective is to improve overall functioning and reduce cannabis-related harms. Most cases of CUD are managed outpatient; inpatient care is reserved for suicidality, psychosis, severe withdrawal, or polysubstance use.[1] Goals may include abstinence or harm reduction (fewer use-days, lower potency, safer routes).[57][58] Early sessions should emphasize engagement and motivational readiness.

Acute Intoxication and Withdrawal

In patients meeting the criteria of acute intoxication and withdrawal, observation and supportive care are primary, and assess for coingestants/suicide risk/psychosis:

• Acute intoxication: Usually self-limited; manage in a calm environment with reassurance and monitoring.

  • Tachycardia/anxiety: supportive psychotherapy first; clonidine or β-blockers briefly, and consider contraindications
  • Severe panic/agitation: short-course benzodiazepines may be used cautiously.
  • Anxiety/insomnia: supportive psychotherapy; consider first-generation antihistamines in moderate to severe symptoms
  • Persistent psychosis: antipsychotics with evaluation for primary psychiatric disorder or coingestants.
• Withdrawal: Onset within 24 hours, peak at 3 days, resolution by 2 weeks.

  • Supportive care is the primary therapy.[57][40]  
  • Hydration, NSAIDs for myalgias
  • Sleep hygiene [59]
  • Clonidine or gabapentin for irritability or insomnia
  • Psychoeducation (monitor mood, suicidality, psychosis)

Psychosocial Interventions (First-Line)

Behavioral therapy is the cornerstone of the management of CUD; combining modalities enhances the effect.[1] Interventions include:

• Brief interventions: 1 to 2 sessions; transient benefit
• CBT: coping skills, triggers, problem-solving; 6 or more sessions [1][60][61]
• Motivational enhancement therapy: readiness enhancement; best when combined with CBT [62]
• Motivational enhancement therapy plus CBT: superior to either alone
• Contingency management: strongest evidence; use if limited early progress.[63]
• Family-based therapy (FBT/MDFT): for adolescents and young adults
• Emerging modalities: Acceptance and Commitment Therapy (ACT) and Dialectical Behavior Therapy (DBT)-informed approaches show early promise
• Digital and telehealth care: Web-based, app-based, or text-based CBT/motivational enhancement therapy/contingency management programs (eg, PNC-txt) expand access and can reduce frequency of use, particularly in stepped-care or rural/low-resource settings [64]
• Mutual-help groups: Marijuana Anonymous, SMART Recovery, or Narcotics Anonymous may support maintenance, though evidence is limited

Treatment Planning and Monitoring

Focus on reducing use-days over grams. Begin weekly, taper as stable. Use urine toxicology by agreement. Include family/partner support. If response is suboptimal, combine CBT plus motivational enhancement therapy with or without contingency management. Reassess regularly and adapt goals.[57]

Pharmacologic and neuromodulation options (investigational)

The following agents or modalities have no FDA-approved pharmacotherapy as evidence remains inconsistent:

• N-acetylcysteine: adolescent signal, not adult-replicated [65]
• [65]Gabapentin: helps sleep/anxiety; sedation risk
• Nabiximols (THC:CBD 1:1): mixed outcomes [66]
• CBD (400–800 mg): reduced THC metabolite ratios and increased abstinent days demonstrated by randomized control studies, but inconsistent replication [67][68]
• Topiramate: may reduce consumption but often limited by adverse effects [69]
• Varenicline, Ketamine-assisted therapy: modest reductions in use-days suggested by small studies
• Semaglutide: retrospective data suggest a lower incidence of CUD; prospective trials are ongoing
• Agents without benefit: antidepressants, mood stabilizers, cannabinoid agonists, atomoxetine, buspirone, zolpidem
• Neuromodulation: rTMS targeting the dorsolateral prefrontal cortex (DLPFC) shows inconsistent results and is not recommended outside research settings [70][71][72]

Comorbidity Management

Comorbidity management requires concurrent treatment of coexisting psychiatric illness to optimize outcomes.[43] Anxiety disorders, depressive disorders, bipolar disorder, posttraumatic stress disorder, and psychotic disorders should receive guideline-concordant treatment alongside interventions for CUD. Cannabis cessation in individuals with psychotic disorders is associated with improved clinical outcomes and reduced relapse risk.[73][74] In patients with attention-deficit/hyperactivity disorder, behavioral therapy and digital interventions, eg, CANreduce 2.0, support meaningful reductions in cannabis use. Targeted management of sleep disturbance, chronic pain, and trauma-related symptoms further reduces relapse vulnerability.

Special Populations and Health Equity

Special populations require tailored, equity-focused approaches. In adolescents, care should prioritize cognitive behavioral therapy, motivational enhancement therapy, and family-based therapy, while pharmacologic options remain investigational.[75] Among veterans and individuals using cannabis for medical purposes, screening with the CUDIT-R and ongoing monitoring for escalation or emerging impairment remain essential. Women and minoritized populations benefit from culturally responsive, flexible models of care that address structural and access-related disparities. In patients with neurologic or pediatric disorders, cannabidiol use should remain limited to specific epilepsies, with specialist oversight required for other indications.

Harm Reduction and Functional Outcomes

Meaningful improvement may occur without full abstinence. Reducing use by roughly 50% in frequency and 75% in total amount is linked to fewer cannabis-related problems and better functioning.[73] Harm reduction focuses on supportive counseling, safe product storage, and preference for lower-THC, non-inhaled forms. Patients should set individualized goals, recognize impairment risks, and understand that links between cannabis use and reduced opioid consumption are correlational, not causal.

Medical Use of Cannabis and Cannabinoids

Cannabis and cannabinoid products show therapeutic benefit in select conditions that are distinct for CUD—chronic pain, chemotherapy-induced nausea and vomiting, multiple sclerosis–related spasticity, and certain epilepsies.[76][77] Evidence for insomnia, anxiety, or appetite stimulation remains of low certainty.[78]

FDA-approved agents include:

• Dronabinol and nabilone: approved for chemotherapy-induced nausea and vomiting and AIDS-related anorexia [79][76]
• [76]Cannabidiol (Epidiolex): approved for Lennox-Gastaut, Dravet, and tuberous sclerosis complex epilepsies

In patients using medical cannabis and cannabinoids, the preferred administration route is noninhaled (eg, oral, sublingual, tinctures). Patients should begin with low doses (eg, 2.5 mg THC ± 2.5 mg CBD) and titrate cautiously. Concurrent use with sedatives or alcohol should be avoided.

Medical-use cannabis and cannabinoids may have adverse effects, including:

• Common: dizziness, somnolence, dry mouth, transient cognitive slowing, anxiety
• Serious: psychosis, cardiovascular events, and cannabinoid hyperemesis syndrome.[80] CBD may mitigate some THC-related adverse effects.

Recommended clinical precautions include:

• Avoid during pregnancy, lactation, psychosis, or unstable cardiac disease.
• Monitor for sedation, cognitive impairment, and CYP450 interactions (eg, warfarin, azoles).[81][82]
• Screen periodically for emerging CUD.
• Reassess every 3 to 6 months for efficacy, adverse effects, product potency, and storage safety; reinforce no driving while impaired.

Medical cannabis may provide modest, condition-specific benefit in carefully selected, refractory cases when standard therapies fail. Thorough counseling, cautious titration, and ongoing monitoring are essential to balance potential benefits against risks.

Differential Diagnosis

CUD must be distinguished from intoxication, withdrawal, other substance use, and primary psychiatric illnesses. Diagnosis depends on the timing of symptoms, degree of impairment, and collateral history.

Substance-Related Conditions

Substance-related conditions that should also be considered include:

• Cannabis-induced states: Intoxication, withdrawal, or cannabis-induced anxiety or psychosis appear during or soon after use and resolve with abstinence.
• Other substances:
  • Stimulants: agitation, tachycardia, mydriasis, psychosis
  • Sedatives/alcohol: withdrawal causes tremor, anxiety, insomnia, and autonomic instability
  • Opioids: intoxication—miosis, respiratory depression; withdrawal—mydriasis, rhinorrhea, GI upset.
  • Hallucinogens: perceptual distortion, panic, derealization.
  • Synthetic cannabinoids: marked agitation, psychosis, seizures, or dysautonomia out of proportion to reported cannabis use.[83][84]

Additionally, clinicians should perform a toxicology when symptoms exceed expected cannabis effects.[85]

Primary Psychiatric Disorders

Cannabis may mimic, precipitate, or coexist with other mental illnesses. Observation during abstinence is essential. Differential diagnoses include:

• Mood and anxiety disorders: Persistent depressive, manic, or anxious symptoms after cessation suggest a primary disorder.
• Neurodevelopmental disorders: ADHD and conduct disorder increase CUD risk but remain independent diagnoses.
• Psychotic disorders: Psychosis preceding use or lasting beyond 1 month of abstinence indicates schizophrenia; cannabis-induced psychosis resolves with abstinence and often follows high-THC exposure.
• Personality disorders: Antisocial or borderline traits may resemble substance-related impulsivity—compare with baseline personality.

Toxicity and Adverse Effect Management

Cannabis toxicity manifests through acute intoxication or effects related to chronic exposure. Short-term use impairs coordination and judgment, increasing the risk of injury and motor vehicle crashes. Pediatric ingestion of edible products frequently causes central nervous system depression and may require emergency evaluation. Synthetic cannabinoids act as potent CB1 and CB2 receptor agonists and produce severe, unpredictable toxicity.[83]

Acute Toxicity

Acute toxicity generally follows a self-limited course and responds to supportive management that includes a calm environment, hydration, benzodiazepines for agitation, and antipsychotics for transient psychosis.[86] Clinical monitoring should focus on tachycardia, hypertension, and arrhythmias, with hospital admission indicated when symptoms persist or involve cardiopulmonary compromise. Following edible ingestion, observation with airway support may be required, along with counseling on safe storage practices.[87] Use of vaping oils warrants additional vigilance, as lipid-adulterated products may precipitate e-cigarette or vaping product use–associated lung injury, managed with supportive respiratory care.

Cannabinoid Hyperemesis Syndrome 

Cannabinoid hyperemesis syndrome causes recurrent nausea and vomiting in chronic users, with symptomatic relief often reported during hot showers.[80][88] Management includes intravenous fluids, antiemetics, topical capsaicin, or antipsychotics, while definitive treatment requires sustained abstinence.[89]

Chronic Toxicity

Chronic toxicity correlates with long-term neurocognitive impairment, mood disorders, and increased cardiovascular stress. Behavioral therapies, including cognitive behavioral therapy, motivational enhancement therapy, and family-based approaches, remain first-line interventions, as pharmacologic agents demonstrate inconsistent benefit.

Synthetic Cannabinoids

Synthetic cannabinoids, including products marketed as K2 or Spice, may provoke agitation, psychosis, seizures, acute kidney injury, myocardial infarction, and death, while routine toxicology screens frequently yield negative results.[83] Management emphasizes airway protection, intravenous fluids, benzodiazepines, temperature control, and consultation with Poison Control. Unexplained bleeding should prompt suspicion of brodifacoum adulteration.[90]

Prognosis

CUD is chronic but often remits with sustained treatment and psychosocial stability. Relapse is common, particularly within the first year, often triggered by stress or comorbid psychiatric symptoms. Early onset, high-THC exposure, and untreated mental illness predict persistent or severe illness. Cognitive function improves within weeks of abstinence, with partial normalization of prefrontal activity on imaging. Integrated behavioral and psychiatric care significantly reduces relapse and improves functioning. Motivation, adherence, and supportive environments are the strongest predictors of long-term recovery and stability.[57][91]

Complications

Early initiation, frequent or high-THC use, polysubstance exposure, and psychiatric comorbidity significantly heighten neuropsychiatric, medical, and functional risks.

Neuropsychiatric and Cognitive

Chronic heavy use impairs attention, memory, and executive function, with alterations in prefrontal, striatal, and hippocampal networks. High-THC exposure increases psychosis risk and relapse after cannabis-induced episodes, while abstinence improves prognosis. CUD is linked to depression and anxiety; perceived symptom relief in posttraumatic stress disorder (PTSD) often diminishes with tolerance and dependence.[92] Women may experience greater vulnerability to anxiety and cognitive effects.[91][93][94][95][96]

Function and Safety

Heavy use correlates with academic and occupational underachievement, lower income, and impaired driving performance. Driving within several hours of use doubles crash risk, particularly with concomitant alcohol use.[97]

Pulmonary and Respiratory

Smoking cannabis causes chronic bronchitic symptoms and airflow limitation independent of tobacco. Vaping THC may precipitate EVALI, and synthetic cannabinoids can provoke seizures or respiratory failure.

Cardiovascular

Cannabis acutely elevates heart rate and myocardial oxygen demand. Meta-analyses associate use with increased myocardial infarction, stroke, and arrhythmia risk, especially in those with underlying cardiovascular disease.

Gastrointestinal

Cannabinoid hyperemesis syndrome presents as cyclic vomiting relieved by hot bathing; management includes fluids, antiemetics, and topical capsaicin, with cessation being curative. High-dose cannabidiol can transiently elevate liver enzymes, though typical exposure rarely causes hepatotoxicity.[98]

Neurologic

Acute intoxication impairs concentration and memory, while chronic exposure reduces processing speed and IQ with partial recovery after abstinence. Neuroimaging demonstrates hippocampal atrophy and cortical thinning in long-term users.[99]

Reproductive and Perinatal

Prenatal exposure increases the risk of low birth weight, preterm birth, and neurobehavioral abnormalities. THC and cannabidiol cross the placenta and accumulate in breast milk; abstinence during pregnancy and lactation is recommended.[100]

Cancer and Other Systems

Associations have been observed with testicular and head–neck cancers, though causality remains inconclusive. Synthetic cannabinoids can cause acute kidney injury and hematologic toxicity. Chronic use may contribute to xerostomia, periodontitis, and metabolic dysregulation.

Mortality and Perioperative Considerations

CUD is associated with increased emergency visits and crash-related mortality. Many deaths involve polysubstance use. Regular users may require higher anesthetic doses and enhanced perioperative monitoring.[101][102][103]

Key Point

High-frequency, high-potency use amplifies neuropsychiatric and systemic complications. Early detection, abstinence counseling, and comorbidity management are critical to reducing morbidity.

Deterrence and Patient Education

Public perception often deems cannabis harmless, yet evidence shows cognitive, psychiatric, and developmental harm—especially in adolescents, young adults, and during pregnancy. Clinicians should provide clear, empathetic counseling and promote harm reduction. Early, frequent, or high-potency use increases dependence, cognitive decline, and psychosis risk. Prenatal exposure impairs fetal growth and neurodevelopment; abstinence is advised. Parents should store cannabis securely to prevent pediatric ingestion, and adults should avoid driving after use. Among users, the risk of CUD is higher in adolescents and in those with frequent or high-potency use. Chronic heavy use heightens risks of psychosis, cognitive deficits, and cannabinoid hyperemesis syndrome. Psychosocial therapies—cognitive behavioral, motivational, contingency-based, and family-centered—are first-line, as no medication is FDA-approved. Education, open dialogue, and community engagement remain key to prevention and recovery.

Pearls and Other Issues

The following factors should be kept in mind in the management of CUD:

• Clinical pearls

  • Most intoxication is self-limited; use a calm setting, reassurance, and hydration
  • Withdrawal: onset 24 hours or less, peak days 2 to 3, resolves in approximately 1 to 2 weeks
  • No FDA-approved meds for CUD; first-line is MI/CBT/contingency/family-based care
• Disposition

  • Outpatient: Uncomplicated intoxication/withdrawal; mild–moderate CUD with follow-up
  • Refer/Admit: Suicidality, persistent psychosis, severe agitation, unstable medical status, pregnancy with heavy use, unsafe setting.
  • Rapid follow-up should be arranged and coordinated with addiction medicine/psychiatry
• Common pitfalls

  • Mislabeling primary mood/psychotic disorders without timing use vs abstinence
  • Using urine THC to infer impairment or diagnose CUD
  • Missing pediatric edible/vape exposures and cannabinoid hyperemesis syndrome; underestimating high-THC/synthetic risks
• Prevention and counseling

  • Patients should be instructed to avoid cannabinoids in pregnancy/lactation; screen and educate routinely
  • Harm reduction: delay initiation, avoid daily/high-THC use, no driving or hazardous work while impaired, avoid mixing with alcohol/sedatives
  • Secure storage (locked, child-resistant); avoid unregulated/adulterated products; ensure longitudinal follow-up

Enhancing Healthcare Team Outcomes

Cannabis and its derivatives, including THC and CBD, produce a range of neuropsychiatric, cognitive, and physiological effects that vary with potency, route of administration, and patient vulnerability. While some cannabis-derived products receive FDA approval for limited indications, widespread recreational and medical use has increased the prevalence of CUD, intoxication, chronic toxicity, and cannabis-related complications such as cannabinoid hyperemesis syndrome and synthetic cannabinoid toxicity. Acute and chronic exposures can impair judgment, cognition, and cardiovascular function, while chronic heavy use elevates risk for mood disorders, neurocognitive deficits, and functional impairment. Special populations, including adolescents, pregnant individuals, veterans, and those with psychiatric or neurologic comorbidities, demonstrate increased susceptibility to adverse effects, highlighting the need for early identification, evidence-based intervention, and individualized care.

Effective management of cannabis-related disorders requires clinicians to integrate validated screening tools, structured diagnostic assessments, and psychosocial treatment strategies while monitoring for acute toxicity, withdrawal, and comorbid psychiatric conditions. Physicians, advanced practitioners, and general practitioners are responsible for diagnosis, initiation of behavioral interventions, and coordination of pharmacologic therapies when indicated. Nurses and pharmacists play essential roles in patient education, monitoring adherence, and identifying adverse effects or drug interactions. Interprofessional communication ensures the timely sharing of clinical findings, alignment on individualized care plans, and rapid response to acute events such as intoxication, synthetic cannabinoid toxicity, or cannabinoid hyperemesis syndrome. Collaborative, team-based care enhances patient safety, supports functional recovery, and promotes consistent application of evidence-based practices across clinical settings.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Le Foll B, Tang VM, Rueda S, Trick LV, Boileau I. Cannabis use disorder: from neurobiology to treatment. J Clin Invest. 2024 Oct 15;134(20) [PMC free article: PMC11473150] [PubMed: 39403927]

2.

ElSohly MA, Majumdar CG, Chandra S, Radwan MM. A 10-year trend in cannabis potency (2013-2022) in different geographical regions of the United States of America. Front Public Health. 2024;12:1442522. [PMC free article: PMC11484017] [PubMed: 39421827]

3.

Solmi M, De Toffol M, Kim JY, Choi MJ, Stubbs B, Thompson T, Firth J, Miola A, Croatto G, Baggio F, Michelon S, Ballan L, Gerdle B, Monaco F, Simonato P, Scocco P, Ricca V, Castellini G, Fornaro M, Murru A, Vieta E, Fusar-Poli P, Barbui C, Ioannidis JPA, Carvalho AF, Radua J, Correll CU, Cortese S, Murray RM, Castle D, Shin JI, Dragioti E. Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies. BMJ. 2023 Aug 30;382:e072348. [PMC free article: PMC10466434] [PubMed: 37648266]

4.

Spiga F, Parkhouse T, Tang VM, Savović J, Le Foll B, Nielsen S. Pharmacotherapies for cannabis use disorder. Cochrane Database Syst Rev. 2025 Sep 30;9(9):CD008940. [PMC free article: PMC12481667] [PubMed: 41025421]

5.

Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-Concentration Delta-9-Tetrahydrocannabinol Cannabis Products and Mental Health Outcomes : A Systematic Review. Ann Intern Med. 2025 Oct;178(10):1429-1440. [PubMed: 40854216]

6.

Levey DF, Galimberti M, Deak JD, Wendt FR, Bhattacharya A, Koller D, Harrington KM, Quaden R, Johnson EC, Gupta P, Biradar M, Lam M, Cooke M, Rajagopal VM, Empke SLL, Zhou H, Nunez YZ, Kranzler HR, Edenberg HJ, Agrawal A, Smoller JW, Lencz T, Hougaard DM, Børglum AD, Demontis D, Veterans Affairs Million Veteran Program. Gaziano JM, Gandal MJ, Polimanti R, Stein MB, Gelernter J. Multi-ancestry genome-wide association study of cannabis use disorder yields insight into disease biology and public health implications. Nat Genet. 2023 Dec;55(12):2094-2103. [PMC free article: PMC10703690] [PubMed: 37985822]

7.

Miller AP, Bogdan R, Agrawal A, Hatoum AS. Generalized genetic liability to substance use disorders. J Clin Invest. 2024 Jun 03;134(11) [PMC free article: PMC11142744] [PubMed: 38828723]

8.

Hatoum AS, Colbert SMC, Johnson EC, Huggett SB, Deak JD, Pathak G, Jennings MV, Paul SE, Karcher NR, Hansen I, Baranger DAA, Edwards A, Grotzinger A, Substance Use Disorder Working Group of the Psychiatric Genomics Consortium. Tucker-Drob EM, Kranzler HR, Davis LK, Sanchez-Roige S, Polimanti R, Gelernter J, Edenberg HJ, Bogdan R, Agrawal A. Multivariate genome-wide association meta-analysis of over 1 million subjects identifies loci underlying multiple substance use disorders. Nat Ment Health. 2023 Mar;1(3):210-223. [PMC free article: PMC10217792] [PubMed: 37250466]

9.

Andrade C. Maternal Cannabis Use During Pregnancy and Maternal and Neonatal Adverse Outcomes. J Clin Psychiatry. 2024 Oct 30;85(4) [PubMed: 39480147]

10.

Gerede A, Stavros S, Chatzakis C, Vavoulidis E, Papasozomenou P, Domali E, Nikolettos K, Oikonomou E, Potiris A, Tsikouras P, Nikolettos N. Cannabis Use during Pregnancy: An Update. Medicina (Kaunas). 2024 Oct 15;60(10) [PMC free article: PMC11509407] [PubMed: 39459478]

11.

Bidwell LC, Karoly HC, Torres MO, Master A, Bryan AD, Hutchison KE. A naturalistic study of orally administered vs. inhaled legal market cannabis: cannabinoids exposure, intoxication, and impairment. Psychopharmacology (Berl). 2022 Feb;239(2):385-397. [PMC free article: PMC12238766] [PubMed: 34708254]

12.

Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021 Feb 25;7(1):16. [PMC free article: PMC8655458] [PubMed: 33627670]

13.

Onaemo VN, Fawehinmi TO, D'Arcy C. Comorbid Cannabis Use Disorder with Major Depression and Generalized Anxiety Disorder: A Systematic Review with Meta-analysis of Nationally Representative Epidemiological Surveys. J Affect Disord. 2021 Feb 15;281:467-475. [PubMed: 33360749]

14.

Quick CR, Conway KP, Swendsen J, Stapp EK, Cui L, Merikangas KR. Comorbidity and Coaggregation of Major Depressive Disorder and Bipolar Disorder and Cannabis Use Disorder in a Controlled Family Study. JAMA Psychiatry. 2022 Jul 01;79(7):727-735. [PMC free article: PMC9161121] [PubMed: 35648395]

15.

Jefsen OH, Erlangsen A, Nordentoft M, Hjorthøj C. Cannabis Use Disorder and Subsequent Risk of Psychotic and Nonpsychotic Unipolar Depression and Bipolar Disorder. JAMA Psychiatry. 2023 Aug 01;80(8):803-810. [PMC free article: PMC10209828] [PubMed: 37223912]

16.

Costa GPA, Nunes JC, Heringer DL, Anand A, De Aquino JP. The impact of cannabis on non-medical opioid use among individuals receiving pharmacotherapies for opioid use disorder: a systematic review and meta-analysis of longitudinal studies. Am J Drug Alcohol Abuse. 2024 Jan 02;50(1):12-26. [PubMed: 38225727]

17.

Choi NG, DiNitto DM, Marti CN, Choi BY. Associations of Healthcare Service Utilization With Cannabis Use Status, Use Reasons, and Use Characteristics Among Those Age 50 and Older. J Appl Gerontol. 2022 May;41(5):1385-1396. [PMC free article: PMC9035048] [PubMed: 35212566]

18.

Young-Wolff KC, Adams SR, Alexeeff SE, Zhu Y, Chojolan E, Slama NE, Does MB, Silver LD, Ansley D, Castellanos CL, Avalos LA. Prenatal Cannabis Use and Maternal Pregnancy Outcomes. JAMA Intern Med. 2024 Sep 01;184(9):1083-1093. [PMC free article: PMC11264060] [PubMed: 39037795]

19.

Wymore EM, Palmer C, Wang GS, Metz TD, Bourne DWA, Sempio C, Bunik M. Persistence of Δ-9-Tetrahydrocannabinol in Human Breast Milk. JAMA Pediatr. 2021 Jun 01;175(6):632-634. [PMC free article: PMC7941249] [PubMed: 33683306]

20.

Tobin T, Xie J, George K. Unintentional Pediatric Ingestion of Cannabis-Addressing a Growing Public Health Risk. JAMA Pediatr. 2023 Oct 01;177(10):993-994. [PubMed: 37603345]

21.

Tweet MS, Nemanich A, Wahl M. Pediatric Edible Cannabis Exposures and Acute Toxicity: 2017-2021. Pediatrics. 2023 Feb 01;151(2) [PubMed: 36594224]

22.

Hasin DS, Wall MM, Choi CJ, Alschuler DM, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Sherman S, Saxon AJ. State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019. JAMA Psychiatry. 2023 Apr 01;80(4):380-388. [PMC free article: PMC9979011] [PubMed: 36857036]

23.

Martinez Ramirez CE, Ruiz-Pérez G, Stollenwerk TM, Behlke C, Doherty A, Hillard CJ. Endocannabinoid signaling in the central nervous system. Glia. 2023 Jan;71(1):5-35. [PMC free article: PMC10167744] [PubMed: 36308424]

24.

Brunt TM, Bossong MG. The neuropharmacology of cannabinoid receptor ligands in central signaling pathways. Eur J Neurosci. 2022 Feb;55(4):909-921. [PMC free article: PMC9291836] [PubMed: 32974975]

25.

Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ. Mechanisms of cannabinoid tolerance. Biochem Pharmacol. 2023 Aug;214:115665. [PMC free article: PMC10528043] [PubMed: 37348821]

26.

Eraso-Pichot A, Pouvreau S, Olivera-Pinto A, Gomez-Sotres P, Skupio U, Marsicano G. Endocannabinoid signaling in astrocytes. Glia. 2023 Jan;71(1):44-59. [PMC free article: PMC9796923] [PubMed: 35822691]

27.

Albaugh MD, Ottino-Gonzalez J, Sidwell A, Lepage C, Juliano A, Owens MM, Chaarani B, Spechler P, Fontaine N, Rioux P, Lewis L, Jeon S, Evans A, D'Souza D, Radhakrishnan R, Banaschewski T, Bokde ALW, Quinlan EB, Conrod P, Desrivières S, Flor H, Grigis A, Gowland P, Heinz A, Ittermann B, Martinot JL, Paillère Martinot ML, Nees F, Papadopoulos Orfanos D, Paus T, Poustka L, Millenet S, Fröhner JH, Smolka MN, Walter H, Whelan R, Schumann G, Potter A, Garavan H., IMAGEN Consortium. Association of Cannabis Use During Adolescence With Neurodevelopment. JAMA Psychiatry. 2021 Jun 16;78(9):1-11. [PMC free article: PMC8209561] [PubMed: 34132750]

28.

Lichenstein SD, Shaw DS, Forbes EE. Cannabis, connectivity, and coming of age: Associations between cannabis use and anterior cingulate cortex connectivity during the transition to adulthood. Front Hum Neurosci. 2022;16:951204. [PMC free article: PMC9692120] [PubMed: 36438638]

29.

Lake S, Murray CH, Henry B, Strong L, White K, Kilmer B, Cooper ZD. High-Potency Cannabis Use and Health: A Systematic Review of Observational and Experimental Studies. Am J Psychiatry. 2025 Jul 01;182(7):616-638. [PMC free article: PMC12549548] [PubMed: 40134269]

30.

Russo EB, Whiteley VL. Cannabinoid hyperemesis syndrome: genetic susceptibility to toxic exposure. Front Toxicol. 2024;6:1465728. [PMC free article: PMC11537899] [PubMed: 39507417]

31.

Cheng W, Parker N, Karadag N, Koch E, Hindley G, Icick R, Shadrin A, O'Connell KS, Bjella T, Bahrami S, Rahman Z, Tesfaye M, Jaholkowski P, Rødevand L, Holen B, Lagerberg TV, Steen NE, Djurovic S, Dale AM, Frei O, Smeland OB, Andreassen OA. The relationship between cannabis use, schizophrenia, and bipolar disorder: a genetically informed study. Lancet Psychiatry. 2023 Jun;10(6):441-451. [PMC free article: PMC10311008] [PubMed: 37208114]

32.

Dumbraveanu C, Strommer K, Wonnemann M, Choconta JL, Neumann A, Kress M, Kalpachidou T, Kummer KK. Pharmacokinetics of Orally Applied Cannabinoids and Medical Marijuana Extracts in Mouse Nervous Tissue and Plasma: Relevance for Pain Treatment. Pharmaceutics. 2023 Mar 06;15(3) [PMC free article: PMC10057980] [PubMed: 36986714]

33.

Chayasirisobhon S. Mechanisms of Action and Pharmacokinetics of Cannabis. Perm J. 2020 Dec;25:1-3. [PMC free article: PMC8803256] [PubMed: 33635755]

34.

Zamarripa CA, Spindle TR, Surujunarain R, Weerts EM, Bansal S, Unadkat JD, Paine MF, Vandrey R. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. JAMA Netw Open. 2023 Feb 01;6(2):e2254752. [PMC free article: PMC9926328] [PubMed: 36780161]

35.

Patilea-Vrana GI, Anoshchenko O, Unadkat JD. Hepatic Enzymes Relevant to the Disposition of (-)-∆⁹-Tetrahydrocannabinol (THC) and Its Psychoactive Metabolite, 11-OH-THC. Drug Metab Dispos. 2019 Mar;47(3):249-256. [PMC free article: PMC6374540] [PubMed: 30567877]

36.

Yabut KCB, Winnie Wen Y, Simon KT, Isoherranen N. CYP2C9, CYP3A and CYP2C19 metabolize Δ9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1). Biochem Pharmacol. 2024 Oct;228:116191. [PMC free article: PMC11410521] [PubMed: 38583809]

37.

Metrik J, Patel S. Alcohol and Cannabinoids - From the Editors. Alcohol Res. 2022;42(1):10. [PMC free article: PMC9232221] [PubMed: 35821767]

38.

Blount BC, Karwowski MP, Shields PG, Morel-Espinosa M, Valentin-Blasini L, Gardner M, Braselton M, Brosius CR, Caron KT, Chambers D, Corstvet J, Cowan E, De Jesús VR, Espinosa P, Fernandez C, Holder C, Kuklenyik Z, Kusovschi JD, Newman C, Reis GB, Rees J, Reese C, Silva L, Seyler T, Song MA, Sosnoff C, Spitzer CR, Tevis D, Wang L, Watson C, Wewers MD, Xia B, Heitkemper DT, Ghinai I, Layden J, Briss P, King BA, Delaney LJ, Jones CM, Baldwin GT, Patel A, Meaney-Delman D, Rose D, Krishnasamy V, Barr JR, Thomas J, Pirkle JL., Lung Injury Response Laboratory Working Group. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N Engl J Med. 2020 Feb 20;382(8):697-705. [PMC free article: PMC7032996] [PubMed: 31860793]

39.

Kesner AJ, Lovinger DM. Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings. J Neurochem. 2021 Jun;157(5):1674-1696. [PMC free article: PMC9291571] [PubMed: 33891706]

40.

Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Clinical management of cannabis withdrawal. Addiction. 2022 Jul;117(7):2075-2095. [PMC free article: PMC9110555] [PubMed: 34791767]

41.

Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9-37. [PMC free article: PMC5414724] [PubMed: 28490916]

42.

Bahji A, Stephenson C, Tyo R, Hawken ER, Seitz DP. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Apr 01;3(4):e202370. [PMC free article: PMC7146100] [PubMed: 32271390]

43.

Chesney E, Reilly TJ, Scott F, Slimani I, Sarma A, Kornblum D, Oliver D, McGuire P. Psychosis associated with cannabis withdrawal: systematic review and case series. Br J Psychiatry. 2024 Dec 03;226(5):1-12. [PMC free article: PMC7617269] [PubMed: 39624030]

44.

Hasin DS, O'Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry. 2013 Aug;170(8):834-51. [PMC free article: PMC3767415] [PubMed: 23903334]

45.

Fink DS, Shmulewitz D, Mannes ZL, Stohl M, Livne O, Wall M, Hasin DS. Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use. J Psychiatr Res. 2022 Nov;155:387-394. [PMC free article: PMC9590423] [PubMed: 36182768]

46.

Gorelick DA. Cannabis-Related Disorders and Toxic Effects. N Engl J Med. 2023 Dec 14;389(24):2267-2275. [PubMed: 38091532]

47.

Shmulewitz D, Budney AJ, Borodovsky JT, Bujno JM, Walsh CA, Struble CA, Livne O, Habib MI, Aharonovich E, Hasin DS. Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use. J Psychiatr Res. 2023 Jul;163:211-221. [PMC free article: PMC10330577] [PubMed: 37224773]

48.

Matson TE, Lapham GT, Bobb JF, Oliver M, Hallgren KA, Williams EC, Bradley KA. Validity of the Single-Item Screen-Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care. JAMA Netw Open. 2022 Nov 01;5(11):e2239772. [PMC free article: PMC9627408] [PubMed: 36318205]

49.

Risi MM, Sokolovsky AW, White HR, Jackson KM. Factor Structure of the Cannabis Use Disorders Identification Test Revised (CUDIT-R) for Men and Women. Cannabis. 2020 Jul 03;3(2):148-156. [PMC free article: PMC10085579] [PubMed: 37041965]

50.

Gryczynski J, Kelly SM, Mitchell SG, Kirk A, O'Grady KE, Schwartz RP. Validation and performance of the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) among adolescent primary care patients. Addiction. 2015 Feb;110(2):240-7. [PMC free article: PMC4301997] [PubMed: 25311148]

51.

Taylor M, Lees R, Henderson G, Lingford-Hughes A, Macleod J, Sullivan J, Hickman M. Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users. Drug Alcohol Rev. 2017 Mar;36(2):220-226. [PMC free article: PMC5396143] [PubMed: 27296783]

52.

Antunes M, Barroso M, Gallardo E. Analysis of Cannabinoids in Biological Specimens: An Update. Int J Environ Res Public Health. 2023 Jan 28;20(3) [PMC free article: PMC9915035] [PubMed: 36767678]

53.

Gendy MNS, Taisir R, Britton E, Costello J, MacKillop J. Rasch Analysis of Cannabis Use Disorder in an Adult Inpatient Sample. Cannabis. 2025;8(2):141-152. [PMC free article: PMC12406237] [PubMed: 40909142]

54.

Metrik J, Stevens AK, Gunn RL, Borsari B, Jackson KM. Cannabis use and posttraumatic stress disorder: prospective evidence from a longitudinal study of veterans. Psychol Med. 2022 Feb;52(3):446-456. [PMC free article: PMC9882422] [PubMed: 32546286]

55.

Livingston NA, Farmer SL, Mahoney CT, Marx BP, Keane TM. Longitudinal course of mental health symptoms among veterans with and without cannabis use disorder. Psychol Addict Behav. 2022 Mar;36(2):131-143. [PMC free article: PMC9048195] [PubMed: 34351175]

56.

Myran DT, Gaudreault A, Pugliese M, Manuel DG, Tanuseputro P. Cannabis-Involved Traffic Injury Emergency Department Visits After Cannabis Legalization and Commercialization. JAMA Netw Open. 2023 Sep 05;6(9):e2331551. [PMC free article: PMC10483310] [PubMed: 37672273]

57.

Ghafouri M, Correa da Costa S, Zare Dehnavi A, Gold MS, Rummans TA. Treatments for Cannabis Use Disorder across the Lifespan: A Systematic Review. Brain Sci. 2024 Feb 28;14(3) [PMC free article: PMC10968391] [PubMed: 38539616]

58.

Shekhawat AS, Mathur R, Sarkar S, Kaloiya GS, Balhara YPS. A randomized controlled trial of brief intervention for patients with cannabis use disorder. J Neurosci Rural Pract. 2023 Oct-Dec;14(4):710-716. [PMC free article: PMC10696312] [PubMed: 38059244]

59.

Lee DC, Schlienz NJ, Herrmann ES, Martin EL, Leoutsakos J, Budney AJ, Smith MT, Tompkins DA, Hampson AJ, Vandrey R. Randomized controlled trial of zolpidem as a pharmacotherapy for cannabis use disorder. J Subst Use Addict Treat. 2024 Jan;156:209180. [PMC free article: PMC12080489] [PubMed: 37802317]

60.

Mauries S, Dufayet G, Lengereau A, Lejoyeux M, Geoffroy PA, Dupong I. Cognitive-behavioral therapies in the management of adolescents with cannabis use disorder (CUD): A systematic review. Drug Alcohol Depend. 2024 Jul 01;260:111321. [PubMed: 38759505]

61.

Halicka M, Parkhouse TL, Webster K, Spiga F, Hines LA, Freeman TP, Sanghera S, Dawson S, Paterson C, Savović J, Higgins JPT, Caldwell DM. Effectiveness and safety of psychosocial interventions for the treatment of cannabis use disorder: A systematic review and meta-analysis. Addiction. 2025 Nov;120(11):2181-2201. [PMC free article: PMC12529236] [PubMed: 40318070]

62.

Connor JP, Manthey J, Hall W, Stjepanović D. Effectiveness of cannabis use and cannabis use disorder interventions: a European and international data synthesis. Eur Arch Psychiatry Clin Neurosci. 2025 Mar;275(2):327-339. [PMC free article: PMC11910397] [PubMed: 38780801]

63.

Lima MG, Tardelli VS, Fidalgo TM. Contingency Management for Cannabis Use Disorder Treatment. Eur Addict Res. 2024;30(5):321-338. [PubMed: 39374591]

64.

Zaharakis N, Coatsworth JD, Riggs NR, Radford A, Rayburn S, Mennis J, Russell MA, Brown A, Mason MJ. Treating young adult cannabis use disorder with text message-delivered peer network counseling. Contemp Clin Trials. 2024 Sep;144:107635. [PubMed: 39019156]

65.

Gray KM, Tomko RL, Baker NL, McClure EA, McRae-Clark AL, Squeglia LM. N-acetylcysteine for youth cannabis use disorder: randomized controlled trial main findings. Neuropsychopharmacology. 2025 Apr;50(5):731-738. [PMC free article: PMC11914066] [PubMed: 39910268]

66.

Mills L, Dunlop A, Montebello M, Copeland J, Bruno R, Jefferies M, Mcgregor I, Lintzeris N. Correlates of treatment engagement and client outcomes: results of a randomised controlled trial of nabiximols for the treatment of cannabis use disorder. Subst Abuse Treat Prev Policy. 2022 Oct 08;17(1):67. [PMC free article: PMC9548192] [PubMed: 36209081]

67.

Freeman TP, Hindocha C, Baio G, Shaban NDC, Thomas EM, Astbury D, Freeman AM, Lees R, Craft S, Morrison PD, Bloomfield MAP, O'Ryan D, Kinghorn J, Morgan CJA, Mofeez A, Curran HV. Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry. 2020 Oct;7(10):865-874. [PMC free article: PMC7116091] [PubMed: 32735782]

68.

Hua DY, Hindocha C, Baio G, Lees R, Shaban N, Morgan CJ, Mofeez A, Curran HV, Freeman TP. Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder. Transl Psychiatry. 2023 Apr 21;13(1):131. [PMC free article: PMC10121552] [PubMed: 37085531]

69.

Miranda R, Treloar H, Blanchard A, Justus A, Monti PM, Chun T, Swift R, Tidey JW, Gwaltney CJ. Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study. Addict Biol. 2017 May;22(3):779-790. [PMC free article: PMC4940362] [PubMed: 26752416]

70.

Sahlem GL, Kim B, Baker NL, Wong BL, Caruso MA, Campbell LA, Kaloani I, Sherman BJ, Ford TJ, Musleh AH, Kim JP, Williams NR, Manett AJ, Kratter IH, Short EB, Killeen TK, George MS, McRae-Clark AL. A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder. Drug Alcohol Depend. 2024 Jan 01;254:111035. [PMC free article: PMC10837319] [PubMed: 38043228]

71.

Wong BL, Kim B, Singh MK, Kim JP, McRae-Clark AL, Sahlem GL. A Secondary Analysis Suggests That Repetitive Transcranial Magnetic Stimulation Applied to the Left Dorsolateral Prefrontal Cortex Reduces Cue-Induced-Craving in Treatment Seeking Participants with Cannabis Use Disorder. medRxiv. 2025 Jan 17; [PubMed: 39867364]

72.

Alayoubi M, Henry BA, Cahill CM, Cooper ZD. Exploring Novel Pharmacotherapy Candidates for Cannabis Use Disorder: Uncovering Promising Agents on the Horizon by Mechanism of Action. Drugs. 2024 Nov;84(11):1395-1417. [PMC free article: PMC11602823] [PubMed: 39388076]

73.

McClure EA, Neelon B, Tomko RL, Gray KM, McRae-Clark AL, Baker NL. Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics. Am J Psychiatry. 2024 Nov 01;181(11):988-996. [PMC free article: PMC12272737] [PubMed: 39380374]

74.

Setién-Suero E, Neergaard K, Ortiz-García de la Foz V, Suárez-Pinilla P, Martínez-García O, Crespo-Facorro B, Ayesa-Arriola R. Stopping cannabis use benefits outcome in psychosis: findings from 10-year follow-up study in the PAFIP-cohort. Acta Psychiatr Scand. 2019 Oct;140(4):349-359. [PubMed: 31381129]

75.

Adams ZW, Marriott BR, Hulvershorn LA, Hinckley JD. Treatment of Adolescent Cannabis Use Disorders. Psychiatr Clin North Am. 2023 Dec;46(4):775-788. [PMC free article: PMC12459973] [PubMed: 37879838]

76.

Bathula PP, Maciver MB. Cannabinoids in Treating Chemotherapy-Induced Nausea and Vomiting, Cancer-Associated Pain, and Tumor Growth. Int J Mol Sci. 2023 Dec 20;25(1) [PMC free article: PMC10779013] [PubMed: 38203245]

77.

Bethoux FA, Farrell R, Checketts D, Sahr N, Berwaerts J, Alexander JK, Skobieranda F. A randomized, double-blind, placebo-controlled trial to evaluate the effect of nabiximols oromucosal spray on clinical measures of spasticity in patients with multiple sclerosis. Mult Scler Relat Disord. 2024 Sep;89:105740. [PubMed: 39106541]

78.

Roberts L, Sorial E, Budgeon CA, Lee K, Preen DB, Cumming C. Medicinal cannabis in the management of anxiety disorders: A systematic review. Psychiatry Res. 2025 Aug;350:116552. [PubMed: 40413923]

79.

Kemmner SF, Dörfler J, Huebner J. Cannabinoids for the prevention of chemotherapy-induced nausea and vomiting in oncological therapy: a systematic review. J Cancer Surviv. 2025 Aug 12; [PubMed: 40797063]

80.

Loganathan P, Gajendran M, Goyal H. A Comprehensive Review and Update on Cannabis Hyperemesis Syndrome. Pharmaceuticals (Basel). 2024 Nov 18;17(11) [PMC free article: PMC11597608] [PubMed: 39598458]

81.

Ho JJY, Goh C, Leong CSA, Ng KY, Bakhtiar A. Evaluation of potential drug-drug interactions with medical cannabis. Clin Transl Sci. 2024 May;17(5):e13812. [PMC free article: PMC11079547] [PubMed: 38720531]

82.

Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, Tegeler K, Trite T, Raup-Konsavage WM, Vrana KE. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and Cannabis. Front Pharmacol. 2024;15:1282831. [PMC free article: PMC11167383] [PubMed: 38868665]

83.

Alzu'bi A, Almahasneh F, Khasawneh R, Abu-El-Rub E, Baker WB, Al-Zoubi RM. The synthetic cannabinoids menace: a review of health risks and toxicity. Eur J Med Res. 2024 Jan 12;29(1):49. [PMC free article: PMC10785485] [PubMed: 38216984]

84.

Prete MM, Feitosa GTB, Ribeiro MAT, Fidalgo TM, Sanchez ZM. Adverse clinical effects associated with the use of synthetic cannabinoids: A systematic review. Drug Alcohol Depend. 2025 Jul 01;272:112698. [PubMed: 40334326]

85.

Mukherji P, Zubair M, Sharma S. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Feb 22, 2026. Toxicology Screening. [PubMed: 29763076]

86.

Chandy M, Nishiga M, Wei TT, Hamburg NM, Nadeau K, Wu JC. Adverse Impact of Cannabis on Human Health. Annu Rev Med. 2024 Jan 29;75:353-367. [PMC free article: PMC10947506] [PubMed: 37582489]

87.

Zwiebel H, Greenky D, Goldman RD. Accidental cannabis ingestion in young children. Can Fam Physician. 2025 Mar;71(3):161-163. [PMC free article: PMC11934634] [PubMed: 40102005]

88.

Hasler WL, Alshaarawy O, Venkatesan T. Cannabis use patterns and association with hyperemesis: A comprehensive review. Neurogastroenterol Motil. 2025 Mar;37(3):e14895. [PubMed: 39164887]

89.

Shine D, Goodin A. Cannabis Hyperemesis Syndrome: What Do We Know? Med Cannabis Cannabinoids. 2024 Jan-Dec;7(1):86-90. [PMC free article: PMC11250556] [PubMed: 39015607]

90.

Bar N, Lopez-Alonso R, Merhav G, Naaman E, Leiderman M, Ilivitzki A, Lurie Y, Kurnik D, Abadi S. Radiological findings in poisoning by synthetic cannabinoids adulterated with brodifacoum. Eur Radiol. 2024 Jul;34(7):4540-4549. [PubMed: 38127072]

91.

Gowin JL, Ellingson JM, Karoly HC, Manza P, Ross JM, Sloan ME, Tanabe JL, Volkow ND. Brain Function Outcomes of Recent and Lifetime Cannabis Use. JAMA Netw Open. 2025 Jan 02;8(1):e2457069. [PMC free article: PMC11775743] [PubMed: 39874032]

92.

Rodas JD, George TP, Hassan AN. A Systematic Review of the Clinical Effects of Cannabis and Cannabinoids in Posttraumatic Stress Disorder Symptoms and Symptom Clusters. J Clin Psychiatry. 2024 Feb 14;85(1) [PubMed: 38353645]

93.

Queiroz APS, Pozzolo Pedro MO, Waisman Campos M, Torales J, Ventriglio A, Castaldelli-Maia JM. Cognitive Effects of Cannabis Use: A Comprehensive Review Across Domains. Neurol Int. 2025 Jul 15;17(7) [PMC free article: PMC12300094] [PubMed: 40710910]

94.

Mahintamani T, Mukherjee D, Basu D. Cannabis and psychopathology: 2024 Snapshot of a meandering journey. Indian J Psychiatry. 2025 Mar;67(3):283-302. [PMC free article: PMC12032589] [PubMed: 40291036]

95.

Matheson J, Behzad D, Zakala C, Hawken T, Brands B, Le Foll B, Wickens CM, Ruocco AC, Rodak T, Di Ciano P. Sex differences in the acute effects of cannabis on human cognition: A systematic review. Front Neuroendocrinol. 2025 Oct;79:101215. [PubMed: 40819776]

96.

Pasquier B, Yaffe K, Levine DA, Rana JS, Pletcher MJ, Tal K, Sidney S, Auer R, Jakob J. Sex Differences in the Association Between Cumulative Use of Cannabis and Cognitive Function in Middle Age: The Coronary Artery Risk Development in Young Adults Study. Cannabis Cannabinoid Res. 2024 Aug;9(4):e1142-e1158. [PubMed: 37594767]

97.

Boicu B, Al-Hakim D, Yuan Y, Brubacher J. Attitudes toward driving after cannabis use: a systematic review. J Cannabis Res. 2024 Sep 28;6(1):37. [PMC free article: PMC11439277] [PubMed: 39342388]

98.

Florian J, Salcedo P, Burkhart K, Shah A, Chekka LMS, Keshishi D, Patel V, Yang S, Fein M, DePalma R, Matta M, Strauss DG, Rouse R. Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults: A Randomized Clinical Trial. JAMA Intern Med. 2025 Sep 01;185(9):1070-1078. [PMC free article: PMC12235532] [PubMed: 40622698]

99.

Ishrat S, Levey DF, Gelernter J, Ebmeier K, Topiwala A. Association between cannabis use and brain structure and function: an observational and Mendelian randomisation study. BMJ Ment Health. 2024 Oct 30;27(1) [PMC free article: PMC11529520] [PubMed: 39477366]

100.

Sainz K, Ulibarri H, Arroyo A, Herrera DG, Hamilton B, Ruffley K, Robinson M, Marchand GJ. Meta-analysis of maternal and neonatal outcomes of cannabis use in pregnancy current to March 2024. Matern Health Neonatol Perinatol. 2025 Aug 01;11(1):20. [PMC free article: PMC12315265] [PubMed: 40745566]

101.

Myran DT, Pugliese M, McDonald AJ, Xiao J, Fischer B, Finkelstein Y, Tanuseputro P, Firth J, Pakpour A, Hsu CW, Chang WC, Solmi M. Cannabis Use Disorder Emergency Department Visits and Hospitalizations and 5-Year Mortality. JAMA Netw Open. 2025 Feb 03;8(2):e2457852. [PMC free article: PMC11803479] [PubMed: 39913138]

102.

Alimoradi Z, Lin CY, Myran DT, Solmi M, Pakpour AH. Relative Risk of All-Cause Mortality Associated With Cannabis Use: A Systematic Review and Meta-Analysis of Cohort Studies. Health Sci Rep. 2025 Oct;8(10):e71212. [PMC free article: PMC12464731] [PubMed: 41017864]

103.

Goudra B, Green M. Perioperative Repercussions of Cannabis Use-Implications for GI Endoscopy Sedation. J Clin Med. 2025 Oct 04;14(19) [PMC free article: PMC12525429] [PubMed: 41096108]

Disclosure: Bala Nimmana declares no relevant financial relationships with ineligible companies.

Disclosure: Sunny Aslam declares no relevant financial relationships with ineligible companies.

Disclosure: Raman Marwaha declares no relevant financial relationships with ineligible companies.